JNJ Stock Price Today (October 2026) — Johnson & Johnson Analysis & Key Metrics 2026-10-08
Johnson & Johnson (JNJ) is trading at $256.48, down 0.76% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $279.27 (8.9% upside).
- Volatility is low (13.63% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (6.60% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
JNJ Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Johnson & Johnson - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $646.37B
P/E Ratio
Forward P/E: 21.60
Revenue Growth
Year over Year
Analyst Target
+8.9% upside potential
Key Investor Questions About JNJ
What investors need to know before buying
Based on current market data, JNJ presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 35.32)
- Fundamentals say: Looking solid (debt and growth supportive)
JNJ's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for JNJ investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $49.04B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, JNJ stock traded between $182.94 and $281.07 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 13.63% annualized volatility and β=-0.08, the stock exhibits low sensitivity to market moves—making JNJ suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
What Does Johnson & Johnson (JNJ) New Clinical Data Mean For Its Stock?
Johnson & Johnson (NYSE:JNJ) reported new clinical data for TECVAYLI plus DARZALEX FASPRO, CARVYKTI, and TREMFYA in multiple myeloma and axial psoriatic arthritis. Early line multiple myeloma data suggest TECVAYLI plus DARZALEX FASPRO could align patient mortality risk with that of the general population. CARVYKTI results highlight treatment-free remissions lasting five years in relapsed or refractory multiple myeloma, while TREMFYA data support an axial psoriatic arthritis label...
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to rethink their income strategy completely.
Johnson & Johnson says Tremfya eases spinal pain in Phase 4 psoriatic arthritis study
Johnson & Johnson (NYSE:JNJ) said its Tremfya treatment significantly improved spinal pain and stiffness in adults with axial psoriatic arthritis in a Phase 4 study. The company said Tremfya met the study’s primary endpoint at week 24, showing greater improvement than placebo on a disease...
J&J’s RYBREVANT Shows Strong Survival. Is J&J’s Oncology Franchise Gaining?
Johnson & Johnson (NYSE:JNJ) already has RYBREVANT approved across multiple EGFR-mutated advanced lung cancer settings. New long-term data are now strengthening the clinical evidence behind the drug. READ ALSO: Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? In the final overall-survival analysis of the Phase 3 PAPILLON study, first-line RYBREVANT plus chemotherapy […]
JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study
J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.
What Johnson & Johnson (JNJ)'s Bipolar I Mania Data for CAPLYTA Means For Shareholders
Johnson & Johnson recently reported positive topline Phase 3 results for CAPLYTA (lumateperone) in adults with bipolar I disorder experiencing manic episodes, showing rapid and statistically significant symptom reduction versus placebo, while also highlighting progress across its broader neuropsychiatry portfolio. The data suggest CAPLYTA could potentially treat both depressive and acute manic episodes in bipolar I disorder, meaningfully broadening its clinical role if future regulatory...
Could You Have Seen Merck Stock's Pipeline Run Coming?
Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.
Why Is JNJ Stock Beating Rivals That Grow Faster?
Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growth ranks only fourth of the six. Three peers grew faster and returned less, Eli Lilly among them. The price is a bet that the rest of the business keeps growing once shrinking STELARA sales stop dragging on the total.
What Could Johnson & Johnson (JNJ) Gain From Its New Immunology Push?
Johnson & Johnson (NYSE: JNJ) received FDA approval for ICOTYDE (icotrokinra) to treat moderate to severe plaque psoriasis in the U.S. ICOTYDE targets the IL-23 receptor and is in Phase III clinical trials for a potential psoriatic arthritis indication. The new therapy extends Johnson & Johnson's immunology pipeline beyond oncology and MedTech into chronic inflammatory skin and joint conditions. The ICOTYDE psoriasis approval and psoriatic arthritis Phase III program deserves weighing...
Explore More Analysis for JNJ
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 13, 2026 (before the open)
Frequently Asked Questions
Common investor questions about Johnson & Johnson
Johnson & Johnson (JNJ) is currently trading at $256.48. The RSI (14-day) is at 35.3, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $279.27 implies 8.9% upside from current levels. Volatility is low at 13.6% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Johnson & Johnson (JNJ): The trailing P/E ratio is 31.11, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 21.60, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 4.66, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 7.55. Price-to-Sales is 6.55. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 22 analysts covering JNJ, the consensus price target is $279.27. This represents a 8.9% upside from the current price of $256.48. The range spans from a low target of $190.00 to a high target of $320.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Johnson & Johnson (JNJ) pays a dividend with a current yield of approximately 2.09%. The annualized dividend rate is $5.24 per share. The payout ratio is 60.8%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was Aug 25, 2026.
Key risks for Johnson & Johnson (JNJ) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Johnson & Johnson's (JNJ) current debt and financial health profile: Total debt stands at $49.04B. The debt-to-equity ratio is 0.58x, which is moderate and generally manageable for most companies. The current ratio is 1.09, indicating adequate short-term liquidity. The quick ratio is 0.73. The company holds $20.76B in cash and equivalents. Free cash flow is positive at $16.89B, providing a cushion for debt servicing and shareholder returns.